Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

NCT06705608 · clinicaltrials.gov ↗

COMPLETED

Status

4000

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Skin Cancer
Skin Cancer Melanoma
Skin Cancers - Basal Cell Carcinoma
Skin Cancer, Squamous Cell
Multiple Sclerosis (MS) - Relapsing-remitting

Interventions

DRUG: Fingolimod
DRUG: Natalizumab
DRUG: Dimethyl fumarate (DMF)
DRUG: Alemtuzumab
DRUG: Teriflunomide

Sponsor

University of British Columbia